ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag legislation disease medicine

Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Cloning Capsized?
Ted Agres | Aug 19, 2001 | 10+ min read
Biopharmaceutical researchers fear how pending federal legislation outlawing the cloning of human cells will restrict their abilities to find cures for major degenerative diseases.1,2 Some also see lawmakers impinging on established nonhuman cloning techniques essential for the discovery of new drugs and therapies. The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) th
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Those We Lost in 2018
Ashley Yeager | Dec 26, 2018 | 10+ min read
The scientific community said goodbye to a number of leading researchers this year.
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
News Notes
Douglas Steinberg | Apr 15, 2001 | 2 min read
A single all-embracing effort to characterize the human proteome is an unlikely prospect (D. Steinberg, "Is a Human Proteome Project Next?" The Scientist, 15[7]:1, April 2, 2001). Nevertheless, smaller-scale--though still massive--proteomics projects keep springing up. On April 4, Myriad Genetics Inc. (MGI), Hitachi Ltd., and Oracle Corp. announced a $185 million, three-year collaboration to identify all protein-protein interactions and biochemical pathways in the human body. Myriad Proteomics I
AIDS Investigators Cautiously Applauding Recent Advances
Steven Benowitz | Sep 29, 1996 | 10+ min read
Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns. AIDS researchers have many reasons to be encouraged. Studies show that treatments combining new and old drugs can control HIV levels in the blood. Moreover, many scientists and activists note, prevention efforts have helped reduce HIV infection rates. Yet the enthusiasm is tempered by several caveats. Drugs are expensive and have harsh side effects, leading
Biosense or Biononsense
Katherine Eban | Apr 1, 2007 | 10+ min read
Biosense or Biononsense? Years of development and hundreds of millions of dollars later, what has the CDC's syndromic surveillance program accomplished?By Katherine Eban ARTICLE EXTRAS Syndromic Surveillance in California It was two days before Thanksgiving 2004, when an epidemiologist in New Jersey's public health agency picked up a heart-stopping electronic message. The
Observers Praise AIDS Report But Foresee Problems In Implementation
Steven Benowitz | May 12, 1996 | 10 min read
Problems In Implementation LOUD AND CLEAR: Attorney Lynda Dee stresses the need for communication among the institutes. When a federally appointed panel announced in March the results of its 15-month-long review of the United States government's AIDS research program, AIDS activists as well as scientists cheered. The National Institutes of Health's AIDS Research Program Evaluation Working Group's recommendations largely called for scrapping what the group saw as outdated and ineffective polic
When Science Has a Potential Payoff
Karen Pallarito(kpallarito@the-scientist.com) | Jan 16, 2005 | 8 min read
In a recent three-hour session at a Chicago hotel room, the University of Wisconsin's technology transfer office hammered out the final details of licensing deal that granted Durham, NC-based Inspire Pharmaceuticals the right to use several patents to develop glau coma treatments.

Run a Search

ADVERTISEMENT